Christopher Haqq, M.D., Ph.D.

Dr. Haqq brings over 20 years of drug development leadership across large and small biotechnology companies and across cell therapy, small molecules, and biologics. He has served as the medical monitor for numerous oncology clinical trials and has worked closely with the U.S. Food and Drug Administration and other global regulatory agencies. Dr. Haqq completed his M.D. and Ph.D. in genetics at Harvard Medical School and his undergraduate training at Stanford University and the University of British Columbia.